Skip to content

Home
Company
Clinical Research
Technology
Partnerships
News
Contact

Home
Company
Clinical Research
Technology
Partnerships
News
Contact

Publications, Papers and Posters

Poster: Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

October 6, 2018

Poster presented at ESMO 2018

Poster: Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies

June 6, 2018

Poster presented at ASCO 2018

Poster: Tumor cell death caused by INT230-6 induces protective T cell immunity

April 6, 2017

Poster presented at AACR 2017

Poster: Intratumoral injection of INT230-6 induces protective T cell immunity

November 6, 2016

Poster presented at SITC 2016

Poster: A novel immunotherapy, INT230-6, is able to induce high rates of complete and durable response in mice through a cytotoxic T-cell-dependent mechanism

April 18, 2016

Poster presented at AACR 2016

Poster: Novel Drug, INT230-6 shows strong synergy with anti-PD-1 Antibodies and can induce high complete response rates with T-cell memory response in a colon cancer mouse model

November 11, 2015

Poster presented at SITC 2015

Poster: INT230-6, a Novel Intratumoral Anticancer Agent, is able to Eradicate Large Established Tumors and Stimulate Potent Antitumor Immunity

April 19, 2015

Poster presented at AACR 2015

Poster: Novel cell penetrating formulation of cytotoxic agents administered intratumorally causes complete regression of large tumors and stimulation of an adaptive immune response in BALB/c syngeneic mice inoculated subcutaneously with murine CT26 colon cancer

October 9, 2014

Poster presented at National Cancer Institute Immunology and Immunotherapy Meeting, October 2014

« Previous Page1 Page2 Next »

Privacy Policy

Menu

Privacy Policy

© 2021 Intensity Therapeutics. All rights reserved.

Linkedin Twitter

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok